Trial Profile
Open multicentre, phase IV study to evaluate efficacy and safety of pegylated interferon alpha-2a (40 KD) plus ribavirin for chronic hepatitis C with normal transaminases in human immunodeficiency virus-infected patients.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Peginterferon alfa-2a (Primary) ; Ribavirin
- Indications Hepatitis C
- Focus Therapeutic Use
- Acronyms CONTRA
- Sponsors Roche
- 12 Sep 2012 New source identified (ClinicalTrials.gov: US National Institutes of Health NCT01684787).
- 15 Nov 2008 New trial record.